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A B S T R A C T
Heart attacks kill more Americans than all cancers combined. Fatal heart attack victims have no symptoms until
minutes before they die, hence early detection of high-risk asymptomatic individuals is needed. Even though
heart attacks kill and cost more than cancers, as a nation we spend over 20 times more on screening for
asymptomatic cancer than for asymptomatic atherosclerotic cardiovascular disease (ASCVD), the underlying
cause of heart attacks. Currently, payers only cover screening for risk factors of ASCVD such as blood pressure
and blood cholesterol. This approach tends to miss high-risk and over-treat low-risk individuals. Although
treadmill stress testing with ECG is not indicated for ASCVD detection in asymptomatic individuals, it is done
often, and frequently leads to misleading conclusions or unnecessary downstream diagnostic procedures. For
example, former President Clinton had passed his treadmill stress tests for several years during his presidential
annual checkup but had a heart attack shortly after his presidency. This common practice is a waste of our
limited resources. Instead, a more accurate risk assessment using coronary artery calcium (CAC) testing is
available; and has just been adopted by ACC/AHA guidelines, however payers do not cover it. CAC is measured
non-invasively with a 5-minute CT-scan of the heart, and costs less than $200, whereas cancer screening with
colonoscopy and mammography costs over $3000. There is an opportunity to save lives and dollars if CAC
testing is covered for appropriately selected individuals. Texas has already passed HB1290 to mandate CAC
coverage. Other states must step up and take actions.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in
America. On average, every 38 s one person dies of CVD in the U.S.
(Benjamin et al., 2017) Unlike cancers for which numerous underlying
pathologies exist, in CVD the majority of deaths and disabilities result
from one underlying pathology: atherosclerosis. Heart attack and stroke
are the two most common manifestations of atherosclerotic cardiovas-
cular disease (ASCVD). Atherosclerosis is a combined metabolic, in-
ﬂammatory, and thrombotic disorder that is chronic and silent until
very late stages. It starts from a gradual deposit of lipids under the
endothelial layer of certain arteries that instigates both cellular and
humoral responses from the body's immune system. Over time this
process leads to the formation of atherosclerotic plaques inside the
arterial wall (Fig. 1).
Such plaques can be found in multiple locations throughout the
arterial tree; however, they are most dangerous in the coronary and
carotid arteries. Due to mechanisms yet to be completely understood,
the vast majority of these plaques become calciﬁed.(Schurgers et al.,
2018) Atherosclerotic plaques may progressively narrow the arterial
lumen without causing symptoms. Certain plaques may become in-
ﬂamed and vulnerable to rupture or erode, resulting in a blood clot that
cuts oﬀ ﬂow downstream. The thrombotic complications of vulnerable
plaques in the coronary arteries results in sudden interruption of blood
ﬂow to myocardium causing a heart attack or sudden death. Similarly,
such complications in the carotid arteries can lead to stroke. Individuals
with vulnerable plaques usually have other characteristics, such as
vulnerable blood and vulnerable myocardium, that contribute to the
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total vulnerability to acute events. Early detection and treatment of
such vulnerable patients have been the focus of research in preventive
cardiology for a long time; unfortunately not much progress has been
made..(Naghavi et al., 2003a; Naghavi et al., 2003b) Heart attack and
stroke cause far more deaths in the US than all cancers combined.
(Benjamin et al., 2017) Despite this sobering fact, screening for
asymptomatic cancer is widely accepted, but screening for asympto-
matic ASCVD is not. Sadly, most patients who die from a heart attack
have no symptoms until about an hour before they die. Since the 1980s,
standards of preventive cardiovascular testing have been limited to
testing for high cholesterol, high blood pressure and other risk factors of
atherosclerosis which were discovered in 1959 by the Framingham
Heart Study.(Dawber et al., 1959) Noninvasive detection of athero-
sclerosis itself by imaging was not possible then, but it is now, and costs
less than a mammography or colonoscopy. Despite a mountain of evi-
dence suggesting that early detection and treatment of ASCVD can save
lives and money, there is no initiative from healthcare policymakers to
change the outdated status quo. Furthermore, there is no ﬁnancial in-
centive for the medical industry to invest in the primary prevention of
ASCVD. Instead, every year the medical industry introduces expensive
new products (catheters, stents, surgical instruments, and pharmaceu-
tical drugs) for treatment of patients during and after a heart attack.
The latter is called secondary prevention, i.e., preventing recurrent
heart attacks. Ironically, the ﬁnancial incentive for prevention of the
second heart attack is far greater than the ﬁnancial incentive for pre-
vention of the ﬁrst heart attack.(Naghavi, 2010) In this paper we review
evidence that indicates that noninvasive detection of atherosclerosis is
superior to the status quo, both for early detection and treatment of
high-risk patients, and for reducing unnecessary therapy in low-risk
individuals. We urge healthcare policymakers to examine the evidence
and take actions similar to that taken in the state of Texas (HB1290,
2006).
2. Cardiovascular disease map
The prevalence of CVD and its most common component, ASCVD, is
increasing across the United States and is expected to double by 2050.
(Casper et al., 2016; Heidenreich et al., 2011) In particular the Southern
and Western regions of the U.S. have the highest prevalence and in-
cidence (Fig. 2).
In the West, Nevada has the highest rate of heart disease followed
by California. In the Southeast, Mississippi has the highest rate of heart
disease followed by Oklahoma. Despite decades of public education
about behavioral risk factors for CVD such as unhealthy diet, the
American Heart Association reported that the prevalence of an ideal
diet score between 2002 and 2012 increased from only 0.7% to 1.5% in
adults, meaning 98.5% of adults are still not following an ideal healthy
diet. The need for new strategies for prevention could not be clearer.
(Writing Group, 2016)
3. What is wrong with the status quo?
Measuring CVD risk factors such as age, smoking, hypertension,
diabetes, and dyslipidemia has been the status quo for estimating the
risk of future ASCVD events. These risk factors are drawn from popu-
lation-based studies and do not translate to personal, speciﬁc risk in an
individual. Many individuals with these risk factors will not experience
an ASCVD event in their lifetime; conversely many patients who actu-
ally experience an ASCVD event do not have a high risk according to
risk calculators. For example, in a study based on American Heart
Fig. 1. A schematic view of a dangerous coronary atherosclerotic plaque. This ﬁgure illustrates various molecular and cellular players in the development of a high-
risk atherosclerotic plaque inside the wall of a coronary artery. Permission obtained from Society for Heart Attack Prevention and Eradication.
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Association's Get with the Guidelines database, 77% of 136,000 patients
who were diagnosed with coronary artery disease in the emergency
room had normal LDL cholesterol levels (Fig. 3).(Sachdeva et al., 2009)
Sir Winston Churchill was 91 when he died in his sleep. He was
overweight and a smoker. In contrast, the famous marathoner, Jim Fixx,
was 53 when he died of a heart attack. He was very ﬁt and did not
smoke. Based on apparent risk factors, Fixx's heart attack risk was fairly
low, and Churchill's was very high. Fixx is not the only marathon
runner who was found to have atherosclerosis. A study was done ex-
amining 49 marathon runners who had participated in over 22 mara-
thons.(Burgstahler et al., 2017) Atherosclerosis was diagnosed in 56%
of the runners.(Casper et al., 2016) None of them smoked, had high
cholesterol, or any other risk factors that stood out. Therefore, the
known ASCVD risk factors do not always tell the full story regarding
who is going to have an ASCVD event. If Jim Fixx had an imaging study
for atherosclerosis, his outcome may have been much diﬀerent.
Another problem with the status quo is that ASCVD kills and costs
more than all cancers combined; nonetheless, investment in screening
for prevention and treatment of asymptomatic ASCVD is far less than
that of cancers. While two types of cancer screening (mammography for
breast cancer and colonoscopy for colorectal cancer) cost over $3000
and are paid for by insurance companies, ASCVD screening is still
limited to less than $100 covered for measuring risk factors (Fig. 4).
Unfortunately, because of lack of insurance coverage, physicians today
are not testing for atherosclerosis.
In summary, the main problem with the status quo is that we as a
nation put more money to ﬁx a heart attack during and after it happens
rather than to prevent it in the ﬁrst place. Furthermore, we use a
Fig. 2. Heart disease death map: South and West have the highest rates. Age-adjusted heart disease death rates in≥35 years old by county and quintile ranking (8).
Fig. 3. Of 136,905 patients hospitalized with CAC, 77% had normal LDL levels below 130mg/dl. Red shows percentage of patients with a normal LDL cholesterol
level but experienced a heart disease event (11).
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population-based statistical tool for risk assessment in an individual to
decide who needs preventive intervention. We need to advance to
personalized risk assessment using noninvasive detection of athero-
sclerosis with a coronary artery calcium (CAC) score, the most studied
and evidence-based test that goes beyond conventional risk assessment.
4. What are the advantages of the CAC score over the status quo?
The proof of the beneﬁts of the CAC test lies in the hundreds of
scientiﬁc studies published so far. Budoﬀ et al. followed over 25,000
asymptomatic patients over 12 years who were referred for coronary
artery calcium scoring. (Budoﬀ et al., 2007) Out of 1000 patients who
had a CAC score of 0, over 99% lived. On the contrary, only 73% of
patients who had a high CAC score over 1000 survived.(Budoﬀ et al.,
2007) Another study of> 85,000 patients showed that those with high
CAC score were 8 times more likely to experience a cardiac event than
those without. (Sarwar et al., 2009) Both studies show us the clear
correlation of a high CAC score to a high risk of an ASCVD event, and
low CAC score to low a risk. Perhaps the strongest evidence favoring
CAC over traditional risk factors came from MESA (Multi-Ethnic Study
of Atherosclerosis), a large NIH (National Institutes of Health) funded
study on ASCVD, that compared noninvasive tests to detect ASCVD in
6800 asymptomatic individuals and followed them for over 10 years.
CAC was the most powerful predictor of ASCVD risk.(Yeboah et al.,
2012) Data from 6 studies of 27,622 asymptomatic patients were
summarized in an ACCF/AHA clinical expert consensus document that
examined predictors of ASCVD events.(Greenland et al., 2007) The
11,815 subjects who had CAC scores of 0 had a low rate of events over
the subsequent 3 to 5 years (0.4%, based on 49 events). CAC scores
between 100 and 400 increased the risk to 4.3% (95% CI 3.5 to 5.2;
p < 0.0001); and scores from 400 to 1000 had a 7.2% risk (95% CI 5.2
to 9.9; p < 0.0001). Any score above 1000 indicated a risk of 10.8%
events over 3–5 years (95% CI 4.2 to 27.7; p < 0.0001). No conven-
tional risk factor has shown such a predictive power. These studies
demonstrate that the relationships between CAC and outcomes are si-
milar in men and women and diﬀerent ethnic groups. Each of these
studies showed that the accuracy to predict coronary artery events is
signiﬁcantly higher with CAC than traditional risk factor-based risk
stratiﬁcation alone. More recently Greenland et al. shed further light on
the clinical implications of CAC for ASCVD risk assessment, proposing
that CAC could be used to guide decisions about statin therapy when
10-year ASCVD risk is 5–20%.(Greenland et al., 2018)
It is noteworthy that a low-hanging fruit in the adoption of CAC can
be found in over 20 million CT scans done annually in the US to screen
for lung cancer (Fig. 5).
Patients can be informed about the presence of CAC on these scans.
Patients with higher levels of calcium in their coronary arteries in-
cidentally detected in these lung scans are more than twice as likely to
Fig. 4. Disparity between the burden of the disease (cardiovascular and cancer) versus the investment made in related preventive screening. Screening test coverage
for primary prevention of cardiovascular disease is< 10% of the coverage for screening for primary prevention of cancer.
Based on data from the National Center for Health and Statistics.
Fig. 5. United States Estimates and Overlap of CAC and Lung Scan Eligible
Patients
The number of eligible patients in the United States is estimated at 33 million
for CAC scanning (yellow) and 7 million for lung scanning in green. Excluding
lung scan eligible patients who have established coronary disease (5.3%, un-
published data from the I-ELCAP database) yields an overlap of 6.6 million lung
scan patients who would be expected to beneﬁt from CAC scanning. Adapted
with permission from: (Hecht HS. Coronary artery calcium scanning: past,
present, and future. JACC Cardiovasc Imaging.)
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die.(Hecht et al., 2014) While there needs to be more research done on
the subject of using CAC for mass screening to improve ASCVD out-
comes, we could improve the status quo if CAC is adopted in a selected
population at intermediate risk. Furthermore, a zero CAC score comes
with a 5-year “warranty” of very low risk suggesting the patient may
not need treatment with a statin. (Min et al., 2010) Even if a patient has
high cholesterol, if their CAC score is zero they will be at low risk for
ASCVD for the next 5 years. Some even argue that they have a low risk
of ASCVD for the next 15 years.(Valenti et al., 2015) These studies
convincingly show that a zero CAC score downgrades risk more than
any other biomarker.(Blaha et al., 2016; Valenti et al., 2015) In the
EISNER trial (Early Identiﬁcation of Subclinical Atherosclerosis by
Noninvasive Imaging Research) investigators studied 2137 patients in
primary prevention clinics.(Rozanski et al., 2011) Half underwent
general clinical and risk factor evaluations, while the other half un-
derwent the same risk factor evaluations plus a coronary calcium scan.
The half that received the scan showed a greater reduction in waist size
and Framingham risk score (e.g., lower blood pressure and cholesterol
levels). The CAC test is also expected to increase patient adherence to
treatment. The phrase “seeing is believing” can apply to CAC. Seeing
calcium in their arteries helps patients visualize their risk and motivates
them to take action.(Maron, 2017)
5. New guidelines based on CAC testing
Over the past decade, a number of the coauthors of this paper have
volunteered with the non-proﬁt SHAPE (Society for Heart Attack
Prevention and Eradication) organization to create a new set of
guidelines that utilizes noninvasive imaging of atherosclerosis, more
speciﬁcally CAC testing.(Naghavi et al., 2006) Our main focus has been
on identiﬁcation of the vulnerable patient.(Naghavi et al., 2006) The
journey to ﬁnd the vulnerable patients began almost two decades ago
with the rise of interest in vulnerable plaques thanks to pioneering work
by Davies et al. (Davies, 1990), Falk et al. (Falk, 1989), Willerson et al.
Fig. 6. In 2006 the SHAPE Task Force proposed the SHAPE Guideline(Naghavi et al., 2006) which is based on noninvasive detection of atherosclerosis using coronary
artery calcium scoring. The higher the burden of atherosclerosis the higher the risk, and the more intensive therapy needed. The “Intermediate Risk” category is the
focus of SHAPE Guideline and results in the majority of ASCVD events.
Table 1
Cost Eﬀectiveness of SHAPE Guidelines. Cost eﬀectiveness modeling predicts ~ $21.5 billion can be saved annually in the U.S. if SHAPE Guidelines are
adopted. (44).
Estimated impact of SHAPE Estimated change in cost: USA
CVD deaths ↓ 10% (5%–25%) ↓ $1.2 B
MI (Prevalence) ↓ 25% (5%–35%) ↓ $18.0 B
Chest pain symptoms (ER Visits) ↓ 5% (2.5%–25%) ↓ $4.1 B
Hospital discharge for primary diagnosis of CVD ↑ 10% (5%–25%) ↑ $3.8 B
Hospital discharge for primary diagnosis of CHD ↓ 10% (5%–25%) ↓ $9.9 B
Cholesterol lowering therapy ↑ 50% (50%–65%) ↑ $8 B
CV imaging ↑ 10% (5%–25%) ↑ $358M
Angiography ↑ 15%-CTA (2.5%–25%) ↑ $600M
PCI (Percutaneous coronary interventions per year) ↓ 10% (5%–50%) ↓ $580M
CABS (Coronary artery bypass surgeries per year) ↓ 5% (2.5%–50%) ↓ $672M
Total Δ in cost $21.5 B
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(Casscells et al., 1996), and Fuster et al. (Fuster et al., 1985) After years
of research and discoveries it became obvious that for primary pre-
vention of ASCVD events we must broaden our scope from vulnerable
plaques to vulnerable patient.(Naghavi et al., 2003a; Naghavi et al.,
2003b)The SHAPE Guidelines were created as the ﬁrst step on the path
toward identifying the vulnerable patient as an increasing mountain of
evidence emerged to indicate that asymptomatic individuals with the
highest level of CAC score had the highest risk and were most vulner-
able to ASCVD events..(Maron, 2017) More recently, we updated the
SHAPE ﬂow-chart in light of the ACC/AHA recommendations (Goﬀ Jr.
et al., 2013). See Fig. 6.
The SHAPE approach has been analyzed by healthcare economy
experts and found to be cost-eﬀective if the CAC test is priced below
$200.(Shaw & Blankstein, 2010) Although the cost of a CAC test used to
be> $400, today it ranges from $100–$200.(Pletcher, 2016) This cost
is insigniﬁcant compared to the cost of stress electrocardiography,
stress echocardiography and nuclear stress tests which are often per-
formed on asymptomatic individuals and cost our healthcare system
millions of dollars. Cost-eﬀectiveness analysis by Shaw et al. indicates
that the US healthcare system could save $21.5 billion dollars annually
if the SHAPE guidelines were adopted.(Shaw et al., 2018) (Table 1).
6. 2018 ACC/AHA cholesterol guideline adopted CAC
The 2018 update to the American College of Cardiology/American
Heart Association guidelines for the management of cholesterol re-
commend CAC measurement when the decision about starting statin
therapy is uncertain from the patient or provider perspective.
According to the new guidelines, withholding or deferring statin in-
itiation is reasonable if CAC=0 and the patient lacks other high-risk
features. If CAC score is ≥100, statin therapy should be started, in-
cluding individuals whose risk estimate falls between 5% and 7.5%.
(Grundy et al., 2018) This is a major change compared to previous
guidelines and acknowledges the abundant evidence that individuals
with CAC ≥100 warrant more intensive preventive therapy and that
individuals with zero coronary calcium are very low risk. Lack of cov-
erage for CAC testing deprives patients from personalized preventive
care and results in undertreatment when therapy is indicated and un-
necessary drug therapy when CAC=0.
7. Texas Heart Attack Eradication Bill and similar initiatives
In 2010, SHAPE helped Texas Representative Rene Oliveira to pass
the HB1290 bill, which requires reimbursement of up to $200 for a CAC
test in men ages 45–75, and women ages 55–75 who fall in the inter-
mediate risk category.(HB1290, 2006; Naghavi, n.d.) This initiative
brought to light the importance of early detection and treatment of CVD
patients without symptoms. Data suggests a possible association be-
tween passing HB1290 and decline in incidence of reported heart dis-
ease in Texas.(Rankings, 2016) (Fig. 7).
Other states are beginning to realize the opportunity to pass similar
bills. The Florida state legislature introduced a bill in 2011 oﬀering
coverage for cardiovascular screening for males over 45 and females
over 55 with low-intermediate risk of CVD. This bill follows SHAPE
guidelines. A similar bill is also under consideration in South Carolina,
to provide reimbursement for CT scans to speciﬁcally test for coronary
calcium in males over 45 and females over 55 with low-intermediate
risk of CVD.(H. 4839, 2017–2018) Now it is time for other states to take
action and make a change for the better.
8. Conclusion
Preventable heart attacks are killing Americans who are not ade-
quately aware of their risk. The current standard of care not only fails to
alert high-risk individuals but also results in potentially unnecessary
drug therapy for low-risk individuals. A more accurate test, CAC score,
is now available; however, insurance companies do not cover it. By
covering CAC score, many will be able to ﬁnd out if they have coronary
plaques. If so, they can be prompted to take preventive actions before a
heart attack occurs. This initiative has the potential to save lives and
money. Texas has already passed HB1290 to mandate CAC coverage.
Other states and other countries can take this cause even further. They
can set the goal to be the ﬁrst to eradicate heart attacks. Although
eradicating heart attacks requires a multipronged long-term approach,
it is now well within our reach; and early detection of high-risk
asymptomatic individuals with CAC testing presents as a low-hanging
fruit. We must strive for a heart attack-free future for the next gen-
eration, the same way that the previous generation gifted us a polio-
and smallpox-free life.
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